#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians who counsel adolescent and young adult patients about cannabis use have commonly cited the “brain development until age 25” threshold as a key risk period, but this review suggests that claim lacks robust scientific support and may undermine credibility in patient discussions. Understanding the actual evidence on cannabis neurotoxicity by age group is essential for providing accurate risk stratification and tailoring prevention messaging to patients based on real rather than assumed developmental vulnerabilities. This clarification allows clinicians to focus cannabis counseling on documented harms specific to younger users while avoiding claims that cannot be substantiated to informed patients.
A comprehensive review by addiction psychiatry researcher Bryon Adinoff, MD, at CU Anschutz challenges the widely cited claim that human brain development continues significantly until age 25, finding this assertion lacks robust scientific support. This finding is clinically relevant because the “brain development until 25” argument has been frequently invoked to justify cannabis restrictions for adolescents and young adults, potentially influencing both clinical counseling and public health policy. The review suggests that while adolescent brains do undergo important maturation, the specific endpoint of age 25 is not supported by evidence-based neurobiology, which has implications for how clinicians communicate cannabis risks to patients across different age groups. Clinicians should be aware that commonly cited neurodevelopmental arguments in cannabis counseling may be oversimplified or based on misinterpretations of the literature, warranting more nuanced discussions with patients about actual evidence-based risks. This distinction matters particularly for young adults, where age-based restrictions or counseling intensity may need reconsideration based on genuine rather than mythologized neuroscience.
“The idea that cannabis exposure uniformly damages the developing brain until age 25 has become dogma in our field, but when you actually examine the neuroscience literature, the evidence for that specific threshold is surprisingly thin, and we’ve done patients a disservice by treating it as settled fact rather than an open clinical question.”
⚕️ The widely cited claim that brain development continues substantially until age 25 deserves scrutiny, particularly given its influence on cannabis policy and clinical counseling about adolescent use. Dr. Adinoff’s critical review challenges this assertion by examining the actual neuroscience literature, finding limited empirical support for such a specific developmental endpoint. Clinicians should recognize that while adolescent brains are undoubtedly still maturing and more vulnerable to some effects of cannabis exposure, the precise timeline and magnitude of continued development remain uncertain and likely vary across brain regions and individuals. This nuance matters because overstated claims can undermine credibility with patients and families while potentially obscuring genuine risks supported by more modest but solid evidence, such as associations between adolescent cannabis use and cognitive outcomes or mental health conditions. When counseling young patients and their families about cannabis, practitioners might emphasize what we do know about developmental vulnerability during the teenage years and early adult
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: